Three oral presentations at ASCO: Selumetinib
Title: Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) (Abstract #7503)
Presenter: Pasi A. Janne, MD, PhD
Date: Monday, June 4, 2012, 5:00 - 5:15 p.m. EDT
Title: Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib (Abstract #5509)
Presenter: Alan L. Ho, MD, PhD
Date: Monday, June 4, 2012, 1:00 - 1:15 p.m. EDT
MEK162
----------
Title: Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations* (Abstract #8511)
Presenter: Paolo A. Ascierto, MD
Date: Monday, June 4, 2012, 4:45 - 5:00 p.m. EDT
The abstracts can be accessed through the ASCO website, http://abstract.asco.org/ . After June 4, 2012, the oral presentation slides will be available as PDFs on Array's website at www.arraybiopharma.com .
*The abstract submitted for MEK162 does not incorporate data and new findings generated since the time of submission in early 2012. The latest and most up-to-date clinical data will be delivered during the investigator's presentation at the Annual Meeting itself, at the date and time listed above.
In addition, the following scientific posters on selumetinib and GDC-0068, an Akt inhibitor partnered with Genentech, will be presented at the conference.
SOURCE: Array BioPharma
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
